Genedrive PLC Commence of roll out in Greater Manchester (4435T)
20 March 2023 - 6:00PM
UK Regulatory
TIDMGDR
RNS Number : 4435T
Genedrive PLC
20 March 2023
genedrive plc
("genedrive" or the "Company")
Genedrive (R) MT-RNR1 to commence roll out in Greater
Manchester
Project to follow NICE final recomendations scheduled for end of
this month
genedrive plc (AIM:GDR), the point of care molecular diagnostics
company, announces that the Genedrive(R) MT-RNR1 ID Kit is in
process for roll out at two further hospital sites in the North
West NHS. The implementation project, scheduled to commence from
April, will follow the NICE final recommendation for the use of the
Genedrive MT-RNR1 ID test in the NHS (England and Wales) which is
due towards the end of this month.
The Manchester Academic Health Science Centre (MAHSC) Women and
Children Domain, part of Health Innovation Manchester (HInM) are
supporting and project managing the further roll out across
Manchester University NHS Foundation Trust. The Company continues
to work alongside HInM on specific plans for the roll out across an
additional five neonatal sites in Greater Manchester. Once fully
subscribed at this regional level, the test would be available when
needed to circa 30000 newborns over the next NHS fiscal year, of
which 10-12% are modelled to be admitted to a regional neonatal
unit.
MAHSC is one of eight national centres designated by NHS England
and the National Institute for Health and Care Research for
demonstrating excellence in patient care and driving innovation
into the health service.
Dr. Ajit Mahaveer, Clinical Head of Division - Newborn Services,
Manchester University NHS Foundation Trust (MFT) said: "The
Genedrive MT-RNR1 test was piloted here at MFT. This initiative
will allow us to expand testing to the neonatal units at North
Manchester General Hospital and Wythenshawe Hospital. We are also
intending to work with NICE on ongoing data collection to support
the long term recommendations for the product."
Jonathan Massey, Programme Director for Academia at Health
Innovation Manchester said: "The Genedrive MT-RNR1 test was
developed alongside our NHS partners and supported by the National
Institute for Health and Care Research. This programme will support
its wider adoption across the city-region, ensuring that the work
done to date will translate to better and equitable patient
outcomes, wherever a child is treated in Greater Manchester."
David Budd, CEO of genedrive plc, said : "While we work with
clinicians and implementers nationally on a Trust by Trust basis,
near-term roll outs such as this one in Greater Manchester will
benefit from additional coordination and support. We are grateful
for the engagement from HInM and MFT, which will be an example for
future regional roll outs elsewhere in the country. It's an
important milestone for the Company as we work to ensuring every
newborn has access to the Genedrive MT-RNR1 ID test when
needed."
The Genedrive(R) MT-RNR1 ID Kit is the world's first commercial
point-of-care genetic test for emergency care. It helps to avoid
irreversible lifelong hearing loss in specific infants exposed to
aminoglycosides by rapidly detecting the m.1555A>G gene variant
that can cause deafness, allowing for alternative antibiotics to be
prescribed. Product information can be found at
https://www.genedrive.com/assays/rnr1-product.php
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Duckworth
finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Alice Lane
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com ) genedrive
plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Company has assays on the market for the detection
of MT-RNR1, HCV, certain military biological targets, a high
throughput SARS-CoV-2 assay and a point of care test for Covid-19.
The company are currently developing a genetic test for CYP2C19
metaboliser status.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBCGDXIDBDGXC
(END) Dow Jones Newswires
March 20, 2023 03:00 ET (07:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2023 to Apr 2024